QRxPHARMA is based in Camberwell, Australia. This company develops and commercializes pharmaceutical products in Australian, U.S and European markets. It is well known for its development of pain management products such as: Moxduo CR and Moxduo IMoxduo IV. The Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. QRxPharma collaborates with other pharmaceutical companies i.e. Aesica Formulation Development Limited to commercialize certain products.